Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We found that vitamin D levels at 12 to 20 weeks were inversely associated with BDI scores both at 12 to 20 and at 34 to 36 weeks’ gestation (P < 0.05, both).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D levels and perinatal depressive symptoms in women at risk: a secondary analysis of the mothers, omega-3, and mental health study

Source: Article title.

This study is a secondary analysis of the data and blood samples of a cohort of women who had enrolled in the Mothers, Omega-3 & Mental Health Study trial, a prospective, double blind, placebo-controlled, randomized controlled trial designed to assess whether omega-3 fatty acid supplementation during pregnancy would prevent antenatal and postpartum depressive symptoms among pregnant women at risk for depression.

Source: Methods.

Women were invited to enroll based on risk factors for perinatal depression, including a past history of depression or postpartum depression, or an Edinburgh Postnatal Depression Scale (EPDS) score of 9 to 19.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D levels and perinatal depressive symptoms in women at risk: a secondary analysis of the mothers, omega-3, and mental health study

Secondary analysis · BMC Pregnancy and Childbirth · 2016

Original publication title

Vitamin D levels and perinatal depressive symptoms in women at risk: a secondary analysis of the mothers, omega-3, and mental health study

Jennifer Anne Williams; Vivian C. Romero; Chelsea M. Clinton; Delia M. Vazquez; Sheila M. Marcus; Julie L. Chilimigras; Susan E. Hamilton; Lucy J. Allbaugh; Anjel M. Vahratian; Ronald M. Schrader; Ellen L. Mozurkewich

© The Author(s). 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In women at risk for depression, early pregnancy low vitamin D levels are associated with higher depressive symptom scores in early and late pregnancy. Future investigations should study whether vitamin D supplementation in early pregnancy may prevent perinatal depressive symptoms.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Vitamin D insufficiency may be associated with depressive symptoms in non-pregnant adults. We performed this study to evaluate whether low maternal vitamin D levels are associated with depressive symptoms in pregnancy.

Source: Background

Abstract: What methods does the paper describe?

This study was a secondary analysis of a randomized trial designed to assess whether prenatal omega-3 fatty acid supplementation would prevent depressive symptoms. Pregnant women from Michigan who were at risk for depression based on Edinburgh Postnatal Depression Scale Score or history of depression were enrolled. Participants completed the Beck Depression Inventory (BDI) and Mini International Neuropsychiatric Interview at 12 to 20 weeks, 26 to 28 weeks, 34 to 36 weeks, and 6 to 8 weeks postpartum. Vitamin D levels were measured at 12 to 20 weeks (N = 117) and 34 to 36 weeks (N = 112).

Complete datasets were available on 105 subjects. Using regression analyses, we evaluated the relationship between vitamin D levels with BDI scores as well as with MINI diagnoses of major depressive disorder and generalized anxiety disorder. Our primary outcome measure was the association of maternal vitamin D levels with BDI scores during early and late pregnancy and postpartum.

Source: Methods

Abstract: Results

We found that vitamin D levels at 12 to 20 weeks were inversely associated with BDI scores both at 12 to 20 and at 34 to 36 weeks’ gestation (P < 0.05, both). For every one unit increase in vitamin D in early pregnancy, the average decrease in the mean BDI score was .14 units. Vitamin D levels were not associated with diagnoses of major depressive disorder or generalized anxiety disorder.

Source: Results

Abstract: Conclusions

In women at risk for depression, early pregnancy low vitamin D levels are associated with higher depressive symptom scores in early and late pregnancy. Future investigations should study whether vitamin D supplementation in early pregnancy may prevent perinatal depressive symptoms.

Source: Conclusions
Authors’ abstract

Background

Vitamin D insufficiency may be associated with depressive symptoms in non-pregnant adults. We performed this study to evaluate whether low maternal vitamin D levels are associated with depressive symptoms in pregnancy.

Methods

This study was a secondary analysis of a randomized trial designed to assess whether prenatal omega-3 fatty acid supplementation would prevent depressive symptoms. Pregnant women from Michigan who were at risk for depression based on Edinburgh Postnatal Depression Scale Score or history of depression were enrolled. Participants completed the Beck Depression Inventory (BDI) and Mini International Neuropsychiatric Interview at 12 to 20 weeks, 26 to 28 weeks, 34 to 36 weeks, and 6 to 8 weeks postpartum. Vitamin D levels were measured at 12 to 20 weeks (N = 117) and 34 to 36 weeks (N = 112).

Complete datasets were available on 105 subjects. Using regression analyses, we evaluated the relationship between vitamin D levels with BDI scores as well as with MINI diagnoses of major depressive disorder and generalized anxiety disorder. Our primary outcome measure was the association of maternal vitamin D levels with BDI scores during early and late pregnancy and postpartum.

Results

We found that vitamin D levels at 12 to 20 weeks were inversely associated with BDI scores both at 12 to 20 and at 34 to 36 weeks’ gestation (P < 0.05, both). For every one unit increase in vitamin D in early pregnancy, the average decrease in the mean BDI score was .14 units. Vitamin D levels were not associated with diagnoses of major depressive disorder or generalized anxiety disorder.

Conclusions

In women at risk for depression, early pregnancy low vitamin D levels are associated with higher depressive symptom scores in early and late pregnancy. Future investigations should study whether vitamin D supplementation in early pregnancy may prevent perinatal depressive symptoms.

Trial registration

https://clinicaltrials.gov/ Registration Number: NCT00711971

Publication and source details

Original title: Vitamin D levels and perinatal depressive symptoms in women at risk: a secondary analysis of the mothers, omega-3, and mental health study

Jennifer Anne Williams; Vivian C. Romero; Chelsea M. Clinton; Delia M. Vazquez; Sheila M. Marcus; Julie L. Chilimigras; Susan E. Hamilton; Lucy J. Allbaugh; Anjel M. Vahratian; Ronald M. Schrader; Ellen L. Mozurkewich

BMC Pregnancy and Childbirth · 2016

© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/100000002National Institutes of HealthAT004166-03S1 (NCCAM)Mozurkewich Ellen L. National Institutes of Health (US) University of MichiganCancer Center Support GrantP30 CA046592UNM Clinical and and Translational Science Center8UL1TR000041

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T09:11:23.511908+00:00

DOI: 10.1186/s12884-016-0988-7 · PMC4971719